Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2967 - Prognostic impact of KRAS mutation in cell-free DNA in patients with pancreatic cancer


11 Sep 2017


Poster display session


Translational Research;  Pancreatic Cancer


Min Kyeong Kim


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


M.K. Kim1, S.M. Woo2, B. Park3, K. Yoon4, Y.H. Kim5, J. Joo3, S.J. Park2, S. Kong6

Author affiliations

  • 1 Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, 10408 - Goyang/KR
  • 2 Center For Liver Cancer, National Cancer Center, 10408 - Goyang/KR
  • 3 Biometric Research Branch, National Cancer Center, 10408 - Goyang/KR
  • 4 College Of Veterinary Medicine, Konkuk University, 05029 - Seoul/KR
  • 5 Molecular Imaging & Therapy Branch, National Cancer Center, 10408 - Goyang/KR
  • 6 7center For Hematologic Malignancy, National Cancer Center, 10408 - Goyang/KR


Abstract 2967


Cell-free DNA (cfDNA) has been known to be released from tumor cells and evaluated potential biomarkers for therapeutic responses. However, the role of cfDNA in pancreatic cancer has not been well studied. Here we selected KRAS mutation which has been known common over 95% of pancreatic ductal adenocarcinoma (PDA) and evaluated applicability as a prognostic marker through the quantitative analysis of cfDNA and KRAS mutation in the patients with PDA.


Total of 106 PDA patients were enrolled in the study. The concentration and fraction of KRAS mutation were measured by KRAS screening multiplex droplet digital PCR kit (Biorad, USA) in plasma samples.


KRAS mutation was detected in 97.4% of tissue samples and the correlation with cfDNA was 0.561 with 80.5% positivity. KRAS mutation concentration and fractional abundance showed the association with poor survival in both PFS (P


This study represents that KRAS mutation concentration and fractional abundance in cfDNA could be prognostic marker in pancreatic cancer especially in resectable group.

Clinical trial identification

Legal entity responsible for the study

Sun-Young Kong


This work was supported by grants from the National Cancer Center of Korea (NCC-1510203).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.